General Atlantic.
$130bn in global capital behind a $4.6bn+, 24-company India book that just ran five exits in 24 months — KFin, PNB Housing, Capital Foods, Rubicon, Amagi — while a $300M+ write-off on Byju's and two 2024 senior India departures sit on the other side of the same ledger.
GW GP Score
General Atlantic is the desk's clearest realisation-versus-franchise split under this rubric. The sell-down machine is running at full pace: three staged KFin Technologies block sales worth roughly ₹3,900 Cr since May 2024, a ₹5,100 Cr strategic sale of Capital Foods to Tata Consumer in January 2024, and IPOs at Rubicon Research, Amagi and TBO Tek all inside eighteen months. Byju's sits on the other side of the same ledger: a board seat and a February 2024 shareholder vote to oust the founder still ended in NCLT insolvency, and General Atlantic's own site now tags the position 'Exited 2024' on what Tracxn puts at a $300M+, 4.8% stake. That was also the year India head Sandeep Naik and India COO Alok Misra both left, with press coverage tying both departures to the Byju's fallout. The live book leans into what General Atlantic does best: mega-checks into category leaders it already owns (PhonePe's stake now at 9% for $1.15bn cumulative since 2023) and rare access into founder-held franchises (Balaji Wafers' first outside capital in 45 years). Franchise risk is real: the test is whether Rastogi's decade of India continuity outweighs one bad year for the bench.
Conditional hold: enough signal to track closely, not enough to underwrite without the next proof point.
The score may understate process quality because realised multiples are modest but repeatable.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Byju's/Think & Learn insolvency: NCLT stayed Form G bidding to an Aug-2026 hearing over an ₹11,433 Cr lender claim — decides whether any recovery reaches equity holders at all.
PhonePe's IPO: paused Mar 2026 with no revised date; watch whether it resumes near the $14.5bn mark GA's Oct-2025 cheque was priced at, against IPO-chatter as low as $9-10.5bn.
Byju's is unresolved: NCLT stayed the insolvency bidding process to an Aug-2026 hearing over an ₹11,433 Cr lender claim — the write-off is booked, but the final recovery, if any, is still in litigation.
Computed from current dossier sources; analyst override pending.
The broadest realisation toolkit the desk has scored under this rubric — block sale, OFS and strategic M&A all producing cash inside the same 24 months — set against a write-off (Byju's, $300M+) large enough to be this cohort's clearest miss, and a 2024 that cost the India franchise both its former head and its COO. Stable, not Positive: the exit engine is proven, the franchise question isn't.
Graded underPrivate equity rubric v1.0→PhonePe/Acko/NoBroker each lead their category, but most are large minority checks (PhonePe 9%, Jio 1.34%) without control rights; Byju's shows a board seat alone didn't protect asset quality
Five cash-or-listing events since Jan 2024 across three routes — KFin (~₹3,900 Cr, 3 tranches), PNB Housing (₹1,033 Cr), Capital Foods (₹5,100 Cr EV sale)
Real roll-ups in healthcare (Ujala Cygnus 9→21 hospitals, ASG's Sharp Sight merger) offset by mega-checks into already-dominant incumbents (PhonePe, Jio, Reliance Retail) with little operating input
Steady ~$1bn/yr India pace since a 2023 disclosure, but PhonePe's Oct-2025 $14.5bn entry sits above the $9-10.5bn IPO chatter that followed the Mar-2026 pause
Rastogi has run India continuously since 2013, but 2024 cost the desk both the prior India/SEA head (Naik) and the India COO (Misra), both linked in press coverage to the Byju's fallout
Asset quality & control 25% · Exit realisation 30% · Value creation 15% · Capital discipline 15% · Franchise stability 15% — the five contributions above sum to 70. Raw scores compare within private equity; across cohorts compare the tier. See the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
PhonePe liquidity clears with credible OFS/block-sale evidence.
Another senior departure or weak attribution on the next fund's named partners.
Byju's/Think & Learn insolvency: NCLT stayed Form G bidding to an Aug-2026 hearing over an ₹11,433 Cr lender claim — decides whether any recovery reaches equity holders at all.
General Atlantic's India book answers the realisation question three different ways at once: KFin's staged block sales, Rubicon's IPO-plus-OFS, Capital Foods' clean strategic sale. That's the diligence template this cohort is graded against. Weigh it against Byju's: a $300M+ position that a board seat and a 2024 vote to oust the founder still couldn't save, now filed under GA's own 'Exited 2024' tag.
Byju's is unresolved: NCLT stayed the insolvency bidding process to an Aug-2026 hearing over an ₹11,433 Cr lender claim — the write-off is booked, but the final recovery, if any, is still in litigation.
Byju's/Think & Learn insolvency: NCLT stayed Form G bidding to an Aug-2026 hearing over an ₹11,433 Cr lender claim — decides whether any recovery reaches equity holders at all.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 0 pressure catalyst(s); top driver: monthly refresh only.
The funds
~$4.6bn deployed in India since 2002 (2023 disclosure); parent AUM $130bn global, all strategies across 1 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| General Atlantic (global growth funds) | evergreen | $130bn AUM (global, all strategies) | Growth → control/buyout | No India-ring-fenced vehicle; deployed off the global balance sheet at a ~$1bn/yr India pace per a 2023 disclosure |
Closest booksADIA (India) (2 shared) · Elevation Capital (2 shared) · Tiger Global (1 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Vehicle cadence is neither freshly restocked nor visibly stale.
Next liquidityPhonePe · Acko · 360 ONE (IIFL Wealth Management) · Rubicon Research · ASG Eye Hospitals
6 visible exit events since Jul 2024.
Vehicle cadence is neither freshly restocked nor visibly stale.
9 up / 6 flat / 5 down tracked signals.
Public senior departures disclosed in the dossier.
9 up / 6 flat / 5 down
6 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangKFin Technologies · Rubicon Research · Unacademy · Amagi · Byju's: names with negative 12-month mark or momentum signals in the reconstructed book.
$1.15bn cumulative since 2023; stake 4.4%→9% via an Oct-2025 $600M secondary at a $14.5bn mark; IPO paused Mar 2026, no revised date
Targeting a $2-2.5bn IPO valuation; confidential DRHP planned H2 2026; FY25 revenue ₹2,837 Cr (+35%), losses cut 37%
Fully exited by Dec 2022 (GA's own portfolio listing dates it 2023); Bain Capital bought 24.98% of the register in Mar 2022
Listed Oct 2025 (103.9x subscribed); stake cut 57.34%→54.01% pre-IPO, then an 8.4% block (₹2,299 Cr) to 27.45% by Nov 2025 — forced fit: pharma/CDMO tagged 'Life Sciences' by GA, closest is Healthcare
Bankers appointed for a ~$500-600M IPO targeting a ~$3.4bn valuation; the Sharp Sight merger extends the roll-up ahead of listing
18% sold in the 2021 IPO OFS, then ₹204 Cr + ₹151 Cr open-market tranches in Sep 2022; fully exited by 2023 per GA's own listing
At least one cited source is dated 2026.
9 visible events tracked.
20 representative positions tracked.
1 departure signals structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 3 · +3
Peer median 2 · +6
Peer median 89 · +1
Peer median 38 · -18
Peer median 0 · +1
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
Watch is visible in the structured people file; past DPI may not be portable to the next vehicle.
Current · At least one cited source is dated 2026.
PhonePe's IPO: paused Mar 2026 with no revised date; watch whether it resumes near the $14.5bn mark GA's Oct-2025 cheque was priced at, against IPO-chatter as low as $9-10.5bn.
Confirm partner roster, board attribution and key-man clauses from firm pages, filings, LP memos or named reporting.
PhonePe's IPO: paused Mar 2026 with no revised date; watch whether it resumes near the $14.5bn mark GA's Oct-2025 cheque was priced at, against IPO-chatter as low as $9-10.5bn.
PhonePe: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
No major evidence gap flagged.
19 total sources · 21% primary
At least one cited source is dated 2026.
General Atlantic: Balaji Wafers strategic investment (Jan 2026)
Maintain monthly source check; escalate on fund close, DRHP, OFS, block sale or senior-partner change.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
24+ companies backed in India since 2002 across three decades of growth capital; 440 companies globally. 20 tracked below, spanning the live book and the 2024-26 realisation wave.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| PhonePe | Fintech | 2023 | Growth (secondary + primary) | Unicorn | → | $1.15bn cumulative since 2023; stake 4.4%→9% via an Oct-2025 $600M secondary at a $14.5bn mark; IPO paused Mar 2026, no revised date |
| Acko | Fintech | 2022 | Growth | Unicorn | → | Targeting a $2-2.5bn IPO valuation; confidential DRHP planned H2 2026; FY25 revenue ₹2,837 Cr (+35%), losses cut 37% |
| Snapmint | Fintech | 2025 | Series B (led, $125M) | Private | ▲ | GA holds 18.8% post-round; FY25 revenue ₹158.5 Cr (+80%), first profitable year (₹15 Cr net) |
| BillDesk | Fintech | 2015 | Growth | Private | ▲ | Single-largest shareholder (~14.2%); PayU's $4.7bn acquisition of BillDesk collapsed in 2022, BillDesk instead bought Worldline's India payments unit for ~$70.8M (Feb 2026) |
| KFin Technologies | Fintech | 2018 | Growth (majority pre-IPO) | Public | ▼ | Listed Dec 2022; stake cut 21.89%→13.14% across three 2024-26 block sales worth ~₹3,900 Cr combined — forced fit: RTA/asset-servicing infrastructure has no clean taxonomy slot |
| 360 ONE (IIFL Wealth Management) | Fintech | 2015 | Minority (21.6%, $173M) | Public | → | Fully exited by Dec 2022 (GA's own portfolio listing dates it 2023); Bain Capital bought 24.98% of the register in Mar 2022 |
| PNB Housing Finance | Fintech | 2016 | Minority | Public | → | 5.1% sold at ₹775/share for ₹1,033 Cr (~$127M), Aug 2024; Carlyle exited its own stake the same year |
| Rubicon Research | Healthcare | 2019 | Control-adjacent majority | Public | ▼ | Listed Oct 2025 (103.9x subscribed); stake cut 57.34%→54.01% pre-IPO, then an 8.4% block (₹2,299 Cr) to 27.45% by Nov 2025 — forced fit: pharma/CDMO tagged 'Life Sciences' by GA, closest is Healthcare |
| Ujala Cygnus | Healthcare | 2024 | Majority (amount undisclosed) | Private | ▲ | Hospital network 9→21 facilities since 2018; prior investors (Eight Roads, Somerset Indus, Evolvence) fully exited on GA's entry |
| ASG Eye Hospitals | Healthcare | 2022 | Co-led with Kedaara (₹1,500 Cr) | Soonicorn | ▲ | Bankers appointed for a ~$500-600M IPO targeting a ~$3.4bn valuation; the Sharp Sight merger extends the roll-up ahead of listing |
| KIMS Hospitals (Krishna Institute of Medical Sciences) | Healthcare | 2018 | Minority (42.6%, $130M+) | Public | ▲ | 18% sold in the 2021 IPO OFS, then ₹204 Cr + ₹151 Cr open-market tranches in Sep 2022; fully exited by 2023 per GA's own listing |
| Reliance Retail | Consumer & Commerce | 2020 | Minority (0.84%, ₹3,675 Cr) | Private | → | Pandemic-era conglomerate cheque at a ₹4.285 lakh Cr pre-money mark; unchanged public marker since |
| Jio Platforms | Logistics & Infra | 2020 | Minority (1.34%, ₹6,598 Cr) | Private | → | Forced fit: telecom/digital infrastructure has no clean taxonomy slot, closest is Logistics & Infra |
| NoBroker.com | Consumer & Commerce | 2019 | Series C (led, $51M) | Unicorn | ▲ | Unicorn since Nov 2021; FY26 revenue >₹1,000 Cr, management targeting profitability in 8-10 months (Sep 2026) |
| TBO Tek | Consumer & Commerce | 2023 | Secondary (from TBO Korea/Augusta TBO) | Public | ▲ | Listed May 2024 at a 50% premium; GA holds ~15% post-IPO — forced fit: B2B travel-distribution platform, closest is Consumer & Commerce |
| Balaji Wafers | Consumer & Commerce | 2026 | Minority (7%, ₹2,050 Cr) | Private | ▲ | Definitive agreement Jan 2026 at a ₹35,000 Cr mark — the Virani family's first outside capital since founding in 1981; close still pending regulatory approval as of this vintage |
| Capital Foods | Consumer & Commerce | 2018 | Minority | Acquired | ▲ | Tata Consumer bought 75% (phasing to 100% over 3 years) at ₹5,100 Cr enterprise value, Jan 2024 — GA exited alongside founder Ajay Gupta and the Invus Group |
| Unacademy | Consumer & Commerce | 2020 | Growth | Acquired | ▼ | upGrad's all-stock deal closed Sep 2026 at ~$206M, 94% below the $3.44bn 2021 peak — forced fit: edtech has no taxonomy slot, closest is Consumer & Commerce |
| Amagi | SaaS & Dev Tools | 2022 | Growth ($100M+, led) | Public | ▼ | Listed Jan 2026 at ₹361; opened at a ~12% discount — GA's weakest IPO debut of the current sell-down wave |
| Byju's | SaaS & Dev Tools | 2018 | Minority (grew to $300M+ across two rounds) | Private | ▼ | 4.8% stake (Tracxn); GA's own site tags the position 'Exited 2024' though Think & Learn remains under NCLT insolvency (bidding stayed to an Aug-2026 hearing) — forced fit: edtech, closest is SaaS & Dev Tools |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
Three cheques in the past twelve months span the range General Atlantic plays at: a $600M secondary top-up into PhonePe (stake to 9%, mostly ESOP liquidity), a $125M Series B lead into Snapmint (the first new India fintech lead check since PhonePe), and a ₹2,050 Cr minority stake in a 45-year-old, founder-controlled snack maker. The pattern is top-up-and-access, not new-logo hunting: deployment continues even as three 2025-26 IPOs occupy the realisation side of the same book.
Stake 4.4%→9%; cumulative $1.15bn since 2023; largely ESOP liquidity ahead of a since-paused IPO
$115M primary + $10M secondary; GA's first new India fintech lead check since PhonePe
The Virani family's first outside capital since founding in 1981; close pending regulatory approval
Realisation · are LPs getting paid?
Five distinct cash-or-listing events since January 2024 — three KFin block sales, a PNB Housing exit, a Capital Foods strategic sale — plus three IPOs (TBO Tek, Rubicon Research, Amagi) still inside their post-listing sell-down windows. Route diversity is the story: block sale, OFS and M&A are all live in the same book at once, which is what a 30%-weighted realisation dimension is built to reward. Byju's and Unacademy's stock-swap sale are the honest counterweight on the same ledger.
8.76% (1.51 Cr shares) sold in an open-market block for ₹1,400 Cr at ₹925/share; stake down to 13.14% from 21.89%, the third tranche after May 2024 (5.8%, ₹712 Cr) and May 2025 (10%, ₹1,790 Cr) — ~₹3,900 Cr banked across the three.
₹1,788.62 Cr IPO priced at ₹361; stock opened at a ~12% discount on listing (21 Jan 2026) — GA's weakest debut of the current sell-down wave.
8.4% stake (1.39 Cr shares) sold for ₹2,299 Cr, cutting the holding to 27.45% from 35.83% five weeks after the IPO.
Listed 16 Oct 2025 at ₹475 (103.9x subscribed); GA's stake had already been cut from 57.34% to 54.01% via a ₹250 Cr pre-IPO placement to TIMF/360 ONE.
5.1% sold at ₹775/share for ₹1,033 Cr (~$127M) in an open-market transaction; Carlyle exited its own PNB Housing stake the same year.
Tata Consumer Products agreed to buy 75% (phasing to 100% over three years) at ₹5,100 Cr enterprise value — GA's exit alongside founder Ajay Gupta and the Invus Group.
Two open-market tranches (₹204 Cr + ₹151 Cr) followed the 18% sold in the 2021 IPO OFS from a 42.6% entry stake; GA's own portfolio listing dates the full exit 2023.
Final tranches sold by Dec 2022, completing the exit from a 21.6% stake bought for $173M in Oct 2015; Bain Capital had already taken 24.98% of the register in Mar 2022 (GA's own site dates the exit 2023).
upGrad's all-stock acquisition closed at ~$206M, 94% below the $3.44bn 2021 peak — a distressed exit for every investor in the cap table, GA included.
KFin (3 tranches), PNB Housing, Capital Foods M&A, plus Rubicon/Amagi/TBO IPOs — block sale, OFS and M&A all firing in the same book
4.8% stake marked 'Exited 2024' on GA's own site — insolvency, not cash; the desk's clearest realisation-record scar
May 2024-Aug 2026: ₹712 Cr + ₹1,790 Cr + ₹1,400 Cr ≈ ₹3,900 Cr banked from a single 2018 entry
India/SEA head Sandeep Naik and India COO Alok Misra both left in 2024, amid Byju's scrutiny
No fund-level DPI is public — General Atlantic runs India off its global evergreen balance sheet, not a ring-fenced India vehicle. GW read: the KFin/PNB Housing/Capital Foods cash trail plus three 2025-26 IPOs is a genuinely diversified realisation record; it sits next to a Byju's write-off large enough to be the single clearest miss in the desk's private-equity coverage. E.
What they're doing
Mega-check top-ups into category leaders it already backs: PhonePe ($1.15bn cumulative since 2023, stake to 9%) and Reliance's Jio/Retail platforms, over new-logo hunting at that end of the book.
Founder-access deals into hold-out family businesses: Balaji Wafers is the Virani family's first outside capital in 45 years, the template GA is trying to repeat across Indian FMCG.
Roll-up consolidation in fragmented healthcare delivery: Ujala Cygnus (9→21 hospitals since 2018) and ASG Eye Hospitals (Sharp Sight merger, IPO bankers appointed) both scale via M&A under GA ownership.
Staged sell-down discipline once a name lists: KFin, Rubicon and now Amagi all show a multi-tranche block-sale programme rather than a single post-lock-up dump.
What can break
Byju's is unresolved: NCLT stayed the insolvency bidding process to an Aug-2026 hearing over an ₹11,433 Cr lender claim — the write-off is booked, but the final recovery, if any, is still in litigation.
2024's dual senior departures (Naik, Misra) were both linked by press coverage to the Byju's fallout; Rastogi's continuity since 2013 is the offsetting fact, but bench depth below him is untested in a comparable crisis.
PhonePe — General Atlantic's largest single India bet at $1.15bn — paused its IPO in March 2026 with no revised date; reported IPO-chatter of $9-10.5bn sits below the $14.5bn mark GA's own October 2025 cheque was priced at.
Large late-stage minority stakes (PhonePe 9%, Jio 1.34%, Reliance Retail 0.84%) carry limited governance leverage: value creation there depends on someone else's operating discipline.
Byju's/Think & Learn insolvency: NCLT stayed Form G bidding to an Aug-2026 hearing over an ₹11,433 Cr lender claim — decides whether any recovery reaches equity holders at all.
PhonePe's IPO: paused Mar 2026 with no revised date; watch whether it resumes near the $14.5bn mark GA's Oct-2025 cheque was priced at, against IPO-chatter as low as $9-10.5bn.
Acko's confidential DRHP (targeted H2 2026) and the $2-2.5bn valuation it prices at — the next public-market test for a GA insurtech bet.
ASG Eye Hospitals' banker-led IPO (~$500-600M raise, ~$3.4bn valuation target) and whether the Sharp Sight-anchored roll-up holds together through the listing process.
Balaji Wafers: the Jan-2026 definitive agreement was still awaiting close as of this vintage, subject to regulatory approval.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
General Atlantic's India book answers the realisation question three different ways at once: KFin's staged block sales, Rubicon's IPO-plus-OFS, Capital Foods' clean strategic sale. That's the diligence template this cohort is graded against. Weigh it against Byju's: a $300M+ position that a board seat and a 2024 vote to oust the founder still couldn't save, now filed under GA's own 'Exited 2024' tag.
Balaji Wafers' structure — first outside capital into a 45-year founder-controlled FMCG house — is the access-deal template worth studying; GA's brand and balance sheet open doors control-focused buyers can't. Its PhonePe/Jio/Reliance Retail cheques also show it will write $500M-1bn+ minority checks most India PE shops can't match, competing on size alone.
The healthcare roll-up pair, Ujala Cygnus and ASG Eye Hospitals, is the read on where consolidation capital is going in Indian healthcare delivery: both are scaling via M&A toward an IPO, not organic bed growth. ASG's $3.4bn IPO target is the next test of whether the multiple survives public markets the way KIMS Hospitals' did, GA's cleanest healthcare exit.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.